Literature DB >> 795582

Immune and phagocytic function in patients on maintenance dialysis and post-transplantation.

C S Hosking, R C Atkins, D F Scott, S R Holdsworth, M G Fitzgerald, M J Shelton.   

Abstract

Immune, phagocytic and opsonic function was assessed in stabilized hemodialysis patients and compared with patients on maintenance immunosuppression following successful renal transplantation. Dialysis patients had a lymphopenia and a qualitative defect in lymphocyte function but opsonic and neutrophil metabolic function was normal. Post-transplant patients had normal intrinsic lymphocyte function but overall immunosuppression due to lymphopenia, selective T cell depletion, and drug inhibition. Neutrophil metabolic function was normal though there was a defect in opsonization.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 795582

Source DB:  PubMed          Journal:  Clin Nephrol        ISSN: 0301-0430            Impact factor:   0.975


  5 in total

Review 1.  The use of vaccines in renal failure.

Authors:  D W Johnson; S J Fleming
Journal:  Clin Pharmacokinet       Date:  1992-06       Impact factor: 6.447

Review 2.  Uraemia--does it affect host resistance to infectious disease?

Authors:  T E Miller
Journal:  Eur J Clin Microbiol       Date:  1984-10       Impact factor: 3.267

3.  The effect of maintenance dialysis on lymphocyte function. I. Haemodialysis.

Authors:  S R Holdsworth; M G Fitzgerald; C S Hosking; R C Atkins
Journal:  Clin Exp Immunol       Date:  1978-07       Impact factor: 4.330

Review 4.  Is hemodialysis a reason for unresponsiveness to hepatitis B vaccine? Hepatitis B virus and dialysis therapy.

Authors:  Dede Sit; Bennur Esen; Ahmet Engin Atay; Hasan Kayabaşı
Journal:  World J Hepatol       Date:  2015-04-18

5.  Splenic abscess associated with endocarditis in a patient on hemodialysis: a case report.

Authors:  Hyun Soo Kim; Min Seok Cho; Seung Hwan Hwang; Seong Kwon Ma; Soo Wan Kim; Nam Ho Kim; Ki Chul Choi
Journal:  J Korean Med Sci       Date:  2005-04       Impact factor: 2.153

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.